Skip to main content

Advertisement

Table 5 Summary of most commonly reported outcomes measures at 12 weeks (or nearest point to). P values relate to active treatment versus placebo or reduced dose. * Indicates a statistical significant difference in favour of EWST treatment. Figures in parentheses are 95% confidence intervals. Where p-values were not provided, the values for mean and standard deviations [SD] are given, I indicates EWST group, II indicates placebo group. "Favours ESWT" indicates a better outcome for ESWT where neither of the previous details are provided.

From: The effectiveness of extra corporeal shock wave therapy for plantar heel pain: a systematic review and meta-analysis

Author Morning/start up pain Overall pain Walking ability /activity related Foot specific score Pain at rest (100 mm VAS) Pain on pressure Night pain/evening pain End point
Abt et al [21] P = 0.016* - Favours ESWT - P = 0.01* P = 0.26 P = 0.01* 19 weeks
Buch et al [27] P = 0.0309 - P = 0.7377 I. (49.1–71.5) II.(32.9–55.9) AOFAS - Not significant P < 0.4338 12 weeks
Buchbinder et al [10] P = 0.92 (-12.7 – 13.1) P = 0.99 (-10.3–11.5) P = 0.0.72 (0.6–1.9) P = 0.85 (-7.6–5.3) Maryland FS - - - 12 weeks
Cosentino et al [33] P < 0.0001* - P < 0.0001* - P < 0.0001* - - 12 weeks
Haake et al [11] I mean = 4.0, SD = 3.2 II mean = 4.5, SD = 3.0 - Favours ESWT - I mean = 2.4, SD = 2.6 II mean = 2.4, SD = 2.5 I mean = 4.0, SD = 3.2 II mean = 4.3, SD = 3.2 I mean = 1.5, SD = 2.4 II mean = 1.8, SD = 2.5 12 weeks
Krischek et al [22] - Favours ESWT Favours ESWT - - Favours ESWT - 12 weeks
Ogden et al [28] Favours ESWT - - - - Favours ESWT - 12 weeks
Rompe et al [32] - - Favours ESWT - P < 0.0001* P < 0.0001* P < 0.0001* 12 weeks
Rompe et al [30] Favours ESWT Favours ESWT P < 0.0001* - P < 0.05* P < 0.0001* P < 0.05* 12 weeks
Rompe et al [31] P = 0.0004* - - P = 0.0025* AOFAS - - - 26 weeks
Speed et al P = 0.664 (0.656–1.271) P = 0.246 (0.626–1.093) - - - - P = 0.378 (0.620–1.166) 12 weeks